Trial reportPsychopharmacology bulletin2009
Neuropsychological functioning in patients with posttraumatic stress disorder following short-term paroxetine treatment.
Trial report in Psychopharmacology bulletin, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The effects of psychological interventions on neurocognitive functioning in posttraumatic stress disorder: a systematic review.European journal of psychotraumatology · 2022Pooled it
- A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples.Neuropsychology review · 2018Pooled it
- A quantitative meta-analysis of neurocognitive functioning in posttraumatic stress disorder.Psychological bulletin · 2015Pooled it
- Post-traumatic stress disorder symptom remission and cognition in a large cohort of civilian women.Psychological medicine · 2024Article
- Neuropsychological Consequences of Massive Trauma: Implications and Clinical Interventions.Medicina (Kaunas, Lithuania) · 2023Review
- Neural correlates of PTSD in women with childhood sexual abuse with and without PTSD and response to paroxetine treatment: A placebo-controlled, double-blind trial.Journal of affective disorders reports · 2023Article
- Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder.International journal of molecular sciences · 2022Review
- Protocol for individual participant data meta-analysis of interventions for post-traumatic stress.BMJ open · 2022Article
- Development and treatment of cognitive inflexibility in sub-chronic stress-re-stress (SRS) model of PTSD.Pharmacological reports : PR · 2021Article
- Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders.Journal of personalized medicine · 2020Review
- Evaluating web-based cognitive-affective remediation in recent trauma survivors: study rationale and protocol.European journal of psychotraumatology · 2018Review
- Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2017Review
- Executive function and PTSD: disengaging from trauma.Neuropharmacology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledA previous study found improvements in verbal declarative memory in patients with Posttraumatic Stress Disorder (PTSD) following one year of open-label paroxetine treatment. The purpose of the present study was to replicate prior findings and to extend the previous study by comparing the effects of paroxetine versus placebo on cognition in patients with PTSD.
methodsEighteen participants with PTSD underwent assessment of neuropsychological function, following which they were randomized to receive controlled-release (CR) paroxetine or placebo, given in a variable dose in a double- blind manner for three months. Neuropsychological testing was then repeated. Subjects who had received placebo were then treated with open-label paroxetine CR and re-assessed.
resultsParoxetine CR treatment resulted in a significant increase in verbal declarative memory function in the group as a whole, as measured by the Wechsler Memory Scale-Revised, the Selective Reminding Test, and novel paragraph recall, and explicit recall of neutral words. Although we found patterns of improved test performance with paroxetine versus placebo treatment, these differences were not statistically significant.
conclusionThese findings replicate an earlier finding that open label treatment with paroxetine CR is associated with improvements in verbal declarative memory function. The current study did not show a statistically significant difference between the effects of paroxetine and placebo on memory function, which may in part be related to our small sample size.
Indexed as
Identifiers
19204651PMC3230323W97871839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.